Infliximab(Remicade®) Pharmacokinetic ELISA
Catalog EL-1611-091

Product Properties

Detection method

Peroxidase / OD450  

Storage and stability

Stable at -20°C for 1 year 

Safety Warnings and Precautions

Research Use Only. Follow instructions. 


Intra-assay coefficient of variation (CV) <10%. Inter-assay CV <10%. 

Detection limit


Each kit includes:

Coated microtiter plate, 96 wells
Calibrator diluent. - 1.8ml
Calibrator (200 ug/mL) - 12ul
10X wash buffer - 25ml
Assay buffer - 50ml
1000X detection reagent - 17ul
TMB - 12ml
TMB stop solution - 12ml
Plate sealers - 3  



Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α). Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located onthe outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.
The Infliximab ELISA kit can be used for monitoring infliximab during clinical research and offers the scientists a tool for understanding of the safety and efficacy of the Infliximab and its biosimilars. The assay design utilizes a pair of antibodies that allows the detection of the whole Inflimximab molecule in biological matrices.
This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti- Infliximab antibody. After washing away any unbound substances, enzyme linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade® (domain residing in Fc portion of the Infliximab® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples. The color development is stopped and the intensity of the color is measured.



There are no reviews yet.

Be the first to review “Infliximab(Remicade®) Pharmacokinetic ELISA
Catalog EL-1611-091”

Your email address will not be published. Required fields are marked *